ArticleAntimicrobial agents and chemotherapy2016
Biofilms of Pathogenic Nontuberculous Mycobacteria Targeted by New Therapeutic Approaches.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 79 citations in OpenAlex.
- Bacterial biofilm conundrum: insight into the frontiers of antibiotic resistance and state-of-the-art anti-biofilm interventions.Frontiers in cellular and infection microbiology · 2026Review
- First evidence of photoinactivation of rapidly growing mycobacteria by tetra-cationic porphyrins with peripheral cisplatin.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- M.marinum lacking epsH shows increased biofilm formation in vitro and boosted antibiotic tolerance in zebrafish.NPJ biofilms and microbiomes · 2025Article
- Review
- Review
- Discovery of Biofilm-Inhibiting Compounds to Enhance Antibiotic Effectiveness AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- Chemical Synthesis and Enzymatic Modification of Mangostins: A Comprehensive Review on Structural Modifications for Drug Discovery.Current medicinal chemistry · 2025Review
- Flavin and deazaflavin biosynthesis in mycobacteria: relevance to physiology, implications for drug discovery, MR-1 antigenicity, and vaccine development.Frontiers in immunology · 2025Review
- Exploring the Multitarget Therapeutic Potential of Mangostin Derivatives.Current medicinal chemistry · 2025Review
- Computational Model to Predict Potential Therapeutic Targets Employing Generative Adversarial Networks for Analysis of Proteins Involved inCurrent medicinal chemistry · 2025Review
- Biofilm Formation in Mycobacterial Genus; Mechanism of Biofilm Formation and Anti-mycobacterial Biofilm Agents.Current pharmaceutical biotechnology · 2025Review
- Article
- Comparative proteomic investigation unravels the pathobiology of Mycobacterium fortuitum biofilm.Applied microbiology and biotechnology · 2023Article
- Characteristics of clinical isolates of nontuberculous mycobacteria in Java-Indonesia: A multicenter study.PLoS neglected tropical diseases · 2022Article
- "Endothelium-Out" and "Endothelium-In" Descemet Membrane Endothelial Keratoplasty (DMEK) Graft Insertion Techniques: A Systematic Review With Meta-Analysis.Frontiers in medicine · 2022Article
- Article
- Hybrid derivative of cathelicidin and human beta defensin-2 against Gram-positive bacteria: A novel approach for the treatment of bacterial keratitis.Scientific reports · 2021Article
- Extracellular DNA of slow growers of mycobacteria and its contribution to biofilm formation and drug tolerance.Scientific reports · 2021Article
- Sulfonamides complexed with metals as mycobacterial biofilms inhibitors.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Genetic Involvement ofInternational journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial infections of the cornea are potentially devastating and can result in permanent visual loss or require vision-rescuing surgery. In recent years, there has been an increasing number of reports on nontuberculous mycobacterial infections of the cornea. Challenges to the management of nontuberculous mycobacterial keratitis include delayed laboratory detection, low index of clinical suspicion, poor drug penetration, slow response to therapy, and prolonged use of antibiotic combinations. The ability of nontuberculous mycobacteria to evade the host immune response and the ability to adhere and to form biofilms on biological and synthetic substrates contribute to the issue. Therefore, there is an urgent need for new antimicrobial compounds that can overcome these problems. In this study, we evaluated the biofilm architectures for Mycobacterium chelonae and Mycobacterium fortuitum in dynamic flow cell chamber and 8-well chamber slide models. Our results showed that mycobacterial biofilms were quite resistant to conventional antibiotics. However, DNase treatment could be used to overcome biofilm resistance. Moreover, we successfully evaluated a new antimicrobial compound (AM-228) that was effective not only for planktonic mycobacterial cells but also for biofilm treatment and was compared favorably with the most successful "fourth-generation" fluoroquinolone, gatifloxacin. Finally, a new treatment strategy emerged: a combination of DNase with an antibiotic was more effective than an antibiotic alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.